Bain-Backed Tanabe Pharma Targets Three New Drug Launches Annually in Japan, Led by Rare Disease Candidate
核心洞察
Bain Capital (搜索)-owned Tanabe Pharma (搜索) plans to launch up to three new drugs per year in Japan through internal R&D and overseas licensing, executives told Reuters.
The company's most promising pipeline asset is a Phase III treatment for erythropoietic protoporphyria (搜索) (EPP), described as "potentially a blockbuster."
Tanabe sold its ALS drug Radicava to Shionogi (搜索) for $2.5 billion to fund new investments and aims for a 20-30% core operating profit-to-sales ratio within three to five years.
Bain Capital (搜索)-owned Tanabe Pharma (搜索) intends to bring up to three new drugs to the Japanese market each year, as the former Mitsubishi Chemical (搜索) unit pivots to an aggressive domestic growth strategy under new leadership, the company's top executives told Reuters in an interview published Tuesday.
Chief Executive Akihisa Harada and Chairman Costa Saroukos outlined a dual-pronged approach combining internal research with the licensing of overseas medicines to rebuild a development pipeline that both executives acknowledged had grown thin under previous ownership.
"Look at many other pharmaceutical companies in Japan in the past five to 10 years — they've really limited the amount of investment in Japan. They just saw Japan as a declining market," said Saroukos, formerly the chief financial officer of Takeda (搜索), Japan's market leader. "This is an opportunity to really double down in Japan, bringing in new, innovative assets and investing in R&D."
A Rare Disease Candidate with Blockbuster Potential
The most advanced asset in Tanabe's own pipeline is a treatment for erythropoietic protoporphyria (搜索) (EPP), a rare disease that causes extreme sensitivity to sunlight. Now in Phase III trials, the drug could be "potentially a blockbuster," Saroukos said.
The company has established a team in the United States tasked with identifying two or three new drugs annually for the Japanese market, with a therapeutic focus on immunology, rare diseases, oncology, and neurology, according to Harada.
Harada, a former president and representative director for Pfizer in Japan, emphasized that Japan's market remains attractive due to significant unmet medical needs among a shrinking and aging population. "All we have to do is look for drugs that have had a lag from the West and then bring them into this country, so I think that's a huge opportunity," he said.
Market Context and Financial Restructuring
Japan is the world's fourth-largest pharmaceutical market, with 2024 sales of approximately $61.6 billion and the highest per capita use of medicines among developed countries, according to health sector researcher IQVIA. However, the market has faced challenges including unpredictable price cuts under the nationalized health scheme and regulatory hurdles that have created a so-called "drug lag" of years between a treatment's U.S. debut and its availability in Japan.
Bain Capital (搜索) acquired Tanabe Pharma (搜索) last year for approximately 510 billion yen ($3.2 billion). Core operating profit amounted to 65.2 billion yen in the drugmaker's final year under the Mitsubishi Chemical (搜索) umbrella — a level the new owners aim to improve significantly.
Earlier this year, Tanabe divested one of its top-selling products, Radicava, a treatment for amyotrophic lateral sclerosis (搜索) (ALS), to Japan-based Shionogi for $2.5 billion to help fund new investments.
The company is targeting a core operating profit-to-sales ratio in the range of 20% to 30%, aligning with domestic competitors. "But it's going to take time. It'll take between three and five years to get there," Saroukos said.
Private Equity Momentum in Japanese Pharma
The Tanabe turnaround effort comes amid a broader surge in private equity-led buyouts in Japan, where regulators and shareholders are increasingly pressuring companies to spin off non-core assets. Japan leads Asia with nearly $14 billion in inbound mergers and acquisitions in 2026 so far, according to LSEG data.
Bain recruited Harada and Saroukos last year to test whether the private equity model can succeed in Japan's fragmented and mature drug market. Tanabe, founded nearly 350 years ago in Osaka, represents one of the country's oldest pharmaceutical enterprises now undergoing a fundamental strategic transformation.